This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Randomized, Controlled Trial of Wax-Matrix Sustained-Release Niacin in Hypercholesterolemia

Joseph M. Keenan, MD; Patricia L. Fontaine, MD; Joyce B. Wenz, RDMS; Shepherd Myers, MA; Zhiquan Huang, MD; Cynthia M. Ripsin, MS

Arch Intern Med. 1991;151(7):1424-1432.

Abstract
Two hundred one male and female subjects, aged 20 to 70 years, with elevated low-density lipoprotein cholesterol values (in the 75th to 95th percentiles), participated in a randomized, controlled, double-blind study using a new form of niacin (Enduracin), which employs a wax-matrix vehicle for sustained release. Four niacin treatment groups (daily doses of 2000, 1500,1250, and 1000 mg) were compared with placebo- and diet-treated controls to determine side-effect profile and optimal range of efficacy. The groups given 2000 and 1500 mg demonstrated significant reductions in values of low-density lipoprotein cholesterol (—26% and —19.3%, respectively), total cholesterol (—18.4% and —13.3%), and total cholesterol-high-density lipoprotein cholesterol ratio ( — 20.4% and —19.4%) when compared with diet- and placebo-treated controls. Smaller improvements were seen in high-density lipoprotein cholesterol and triglyceride levels. Blood chemistry monitoring indicated that reduction in low-density lipoprotein cholesterol level strongly correlated with an increase in baseline levels of some enzymes for niacintreated subjects. The improved side-effect profile of the wax-matrix form of niacin was particularly notable. The dropout rate due to side effects was only 3.4% and was coupled with good medication compliance.

(Arch Intern Med. 1991;151:1424-1432)

Author Affiliations
From the Department of Family Practice and Community Health, University of Minnesota, Minneapolis.

Footnotes
Accepted for publication November 14, 1990.

Reprint requests to Department of Family Practice, 825 Washington Ave SE, Box25, Minneapolis, MN 55414(Dr Keenan).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trials
Birjmohun et al.
J Am Coll Cardiol 2005;45:185-197.
ABSTRACT | FULL TEXT  

New Perspectives on the Use of Niacin in the Treatment of Lipid Disorders
McKenney
Arch Intern Med 2004;164:697-705.
ABSTRACT | FULL TEXT  

Varying Cost and Free Nicotinic Acid Content in Over-the-Counter Niacin Preparations for Dyslipidemia
Meyers et al.
ANN INTERN MED 2003;139:996-1002.
ABSTRACT | FULL TEXT  

High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased Km): relevance to genetic disease and polymorphisms
Ames et al.
Am. J. Clin. Nutr. 2002;75:616-658.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Cholesterol-Lowering Therapies according to Selected Patient Characteristics
Prosser et al.
ANN INTERN MED 2000;132:769-779.
ABSTRACT | FULL TEXT  

Extended-Release Niacin vs Gemfibrozil for the Treatment of Low Levels of High-Density Lipoprotein Cholesterol
Guyton et al.
Arch Intern Med 2000;160:1177-1184.
ABSTRACT | FULL TEXT  

Forecasting Patient Outcomes in the Management of Hyperlipidemia
Brier et al.
Arch Intern Med 1999;159:569-575.
ABSTRACT | FULL TEXT  

Cost-effective Treatment of Hypercholesterolemia
Parsons et al.
Arch Intern Med 1998;158:1723-1724.
FULL TEXT  

Clinical Trial of Wax-Matrix Sustained-Release Niacin in a Russian Population With Hypercholesterolemia
Aronov et al.
Arch Fam Med 1996;5:567-575.
ABSTRACT  

Cholesterol-Reduction Intervention Study (CRIS) A Randomized Trial to Assess Effectiveness and Costs in Clinical Practice
Oster et al.
Arch Intern Med 1996;156:731-739.
ABSTRACT  

Patient-Directed, Nonprescription Approaches to Cardiovascular Disease
Simon
Arch Intern Med 1994;154:2283-2296.
ABSTRACT  

Safety and Side Effects of Sustained-Release Niacin
Keenan et al.
JAMA 1994;272:513-513.
ABSTRACT  

A Comparison of the Efficacy and Toxic Effects of Sustained- vs Immediate-Release Niacin in Hypercholesterolemic Patients
McKenney et al.
JAMA 1994;271:672-677.
ABSTRACT